Is Gujarat Themis Biosyn a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Gujarat Themis Biosyn Ltd is a good quality company .

Is Gujarat Themis Biosyn undervalued or overvalued?

The key valuation ratios of Gujarat Themis Biosyn Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Gujarat Themis Biosyn share price return in the past 10 years?

Gujarat Themis Biosyn Ltd share price has appreciated 67% annually (CAGR) over the past ten years.

Is Gujarat Themis Biosyn a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Gujarat Themis Biosyn Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

What is the P/E ratio of Gujarat Themis Biosyn?

The latest standalone P/E ratio of Gujarat Themis Biosyn as of 19-Apr-2024 is 50.99.

What is the P/B ratio of Gujarat Themis Biosyn?

The latest standalone P/B ratio of Gujarat Themis Biosyn as of 19-Apr-2024 is 14.67.

What is the 52-week high and low of Gujarat Themis Biosyn?

The 52-week high of Gujarat Themis Biosyn is Rs. 410.00 and the 52-week low is Rs. 144.51.

What is the TTM revenue of Gujarat Themis Biosyn?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Gujarat Themis Biosyn is Rs. 156.27 (Cr.).

Gujarat Themis Biosyn Ltd - Stock Valuation and Financial Performance

Name: Gujarat Themis Biosyn
Brand: Gujarat Themis Biosyn

BSE: 506879 | NSE: GUJTHEMIS | Pharmaceuticals & Drugs | Small Cap

Place order

Guj. Themis Biosyn Share Price

₹379.50 -3.55 -0.93%
as on 19-Apr'24 16:01

10 Year X-Ray of Guj. Themis Biosyn:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
ROCE % ⓘ	200.1%	115.8%	79.2%	48.1%	33.4%	34.8%	65%	50.1%	50.1%	46%	-
Value Creation Index ⓘ	13.3	7.3	4.7	2.4	1.4	1.5	3.6	2.6	2.6	2.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	30.2	31.4	32.6	35.7	38.8	41.1	85.1	90.6	115	149	156
Sales YoY Gr.	-	4%	3.8%	9.4%	8.7%	5.8%	107.4%	6.4%	26.8%	29.7%	-
Adj EPS ⓘ	0.6	0.7	0.6	0.6	0.5	0.9	3.3	4.2	6	8	7.6
YoY Gr.	-	6.5%	-3%	-6.3%	-11.7%	66%	270.5%	27.3%	44.6%	33%	-
BVPS (₹) ⓘ	-0.7	-0.1	0.5	1.1	1.7	2.6	5.8	9.6	14.2	20.5	26.3
Adj Net Profit ⓘ	4.5	4.8	4.7	4.4	3.9	6.4	23.7	30.2	43.6	58	55
Cash Flow from Ops. ⓘ	4.3	2.7	3.9	2.8	5.6	0.7	0.6	10.5	40.3	39.5	-
Debt/CF from Ops. ⓘ	2.1	2.2	0.9	1.4	0.1	8.8	12.9	0.3	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	19.4%	30.9%	20.5%	29.7%
Adj EPS ⓘ	32.8%	72%	34.8%	33%
BVPSⓘ	NA	65.2%	52.3%	44.4%
Share Price	67%	118.4%	103.2%	155.4%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	-59.4	-156.7	305.1	72.5	38.1	41.6	78	53.8	50.4	45.9	32.3
Op. Profit Mgn % ⓘ	21.5	20.9	18.7	17	16.1	17.9	37.4	44.5	50.5	49.8	46.7
Net Profit Mgn % ⓘ	14.9	15.3	14.3	12.2	10	15.5	27.8	33.3	38	38.9	35.2
Debt to Equity ⓘ	-1.7	-7.7	0.9	0.5	0.1	0.3	0.2	0	0	0	-
Working Cap Days ⓘ	56	50	55	78	73	92	144	204	226	265	76
Cash Conv. Cycle ⓘ	-54	-52	-47	-26	-22	-19	27	54	62	47	55

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 20.51%

Net Profit is growing at healthy rate in last 3 years 34.77%

Return on Equity has declined versus last 3 years average to 32.30%

Sales growth is not so good in last 4 quarters at 7.36%

Latest Financials - Gujarat Themis Biosyn Ltd.

	Standalone	Consolidated
TTM EPS (₹)	7.6	-
TTM Sales (₹ Cr.)	156	-
BVPS (₹.) ⓘ	26.3	-
Reserves (₹ Cr.) ⓘ	184	-
P/BV ⓘ	14.67	-
PE ⓘ	50.99	-

From the Market
52 Week Low / High (₹)	144.51 / 410.00
All Time Low / High (₹)	0.30 / 410.00
Market Cap (₹ Cr.)	2,803
Equity (₹ Cr.)	7.3
Face Value (₹)	1
Industry PE ⓘ	47.2

Management X-Ray of Guj. Themis Biosyn:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

3.30

* Pledged shares as % of Promoter's holding (%)

Valuation of Guj. Themis Biosyn

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Guj. Themis Biosyn

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Sales	30	31	33	36	39	41	85	91	115	149
Operating Expenses ⓘ	24	25	27	30	33	34	53	50	57	75
Manufacturing Costs	19	19	21	22	24	26	34	26	31	37
Material Costs	0	0	0	1	2	1	11	15	16	26
Employee Cost	4	4	4	4	4	5	6	7	7	8
Other Costs ⓘ	1	1	1	1	2	2	2	2	3	4
Operating Profit ⓘ	7	6	6	6	6	7	32	40	58	74
Operating Profit Margin (%)	21.5%	19.9%	18.5%	16.9%	16.1%	17.9%	37.4%	44.5%	50.5%	49.8%
Other Income ⓘ	0	0	0	0	0	2	2	3	4	6
Interest ⓘ	1	0	0	0	0	0	1	1	1	0
Depreciation ⓘ	1	1	1	1	1	1	1	2	2	3
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	5	5	5	5	5	8	31	41	59	77
Tax ⓘ	0	0	0	1	1	2	8	11	15	19
Profit After Tax	5	5	5	4	4	6	24	30	44	58
PAT Margin (%)	15.0%	14.6%	14.2%	12.3%	10.0%	15.6%	27.8%	33.3%	38.0%	38.9%
Adjusted EPS (₹)	0.6	0.6	0.6	0.6	0.5	0.9	3.3	4.2	6.0	8.0
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	10%	0%	37%	14%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	-5	-1	4	8	12	19	42	70	103	149
Share Capital ⓘ	7	7	7	7	7	7	7	7	7	7
Reserves ⓘ	-13	-8	-3	1	5	11	35	63	96	142
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	8	5	1	2	0	0	3	0	0	0
Long Term Debt	6	5	1	1	0	0	3	0	0	0
Short Term Debt	2	0	0	1	0	0	0	0	0	0
Trade Payables	5	6	6	7	6	6	7	4	7	10
Others Liabilities ⓘ	8	5	4	4	3	9	18	25	27	28
Total Liabilities ⓘ	16	15	15	21	20	33	71	98	137	187
Fixed Assets
Gross Block	43	41	42	12	13	18	22	26	28	44
Accumulated Depreciation	32	31	32	1	2	3	5	7	9	11
Net Fixed Assetsⓘ	11	10	9	11	11	15	17	19	19	33
CWIP ⓘ	0	0	0	0	0	1	0	2	13	21
Investmentsⓘ	0	0	0	0	0	0	0	0	0	0
Inventories	0	0	0	1	0	0	6	6	12	15
Trade Receivables	1	2	2	7	3	6	20	15	25	18
Cash Equivalents	1	0	0	0	4	2	2	28	12	9
Others Assetsⓘ	2	2	2	3	2	9	25	29	56	92
Total Assets ⓘ	16	15	15	21	20	33	71	98	137	187

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	4	3	4	3	6	1	1	11	40	40
PBT ⓘ	5	5	5	5	5	8	31	41	59	77
Adjustment ⓘ	2	2	2	1	1	-4	1	0	0	-2
Changes in Working Capital ⓘ	-2	-4	-2	-3	-0	-2	-24	-20	-4	-15
Tax Paid ⓘ	0	0	-1	-1	-1	-1	-7	-10	-15	-20
Cash Flow From Investing Activity ⓘ	0	0	-1	-3	-1	-6	-3	-2	-30	-20
Capex	0	0	-1	-3	-1	-6	-3	-3	-14	-24
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	0	0	1	-16	3
Cash Flow From Financing Activityⓘ	-3	-3	-3	0	-4	5	2	-5	-14	-13
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-1	0	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	0	0	0	0	0	0	0	-2	-10	-12
Others ⓘ	-3	-3	-3	0	-4	5	2	-2	-4	-1
Net Cash Flow ⓘ	1	-1	0	0	1	0	0	3	-4	6

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'14	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23
Ratios
ROE (%)	N/A	N/A	302.71	72.63	38.06	41.85	77.99	53.82	50.35	45.92
ROCE (%)	N/A	N/A	80.38	54.67	42.22	44.88	85.96	67.89	67.91	61.53
Asset Turnover Ratio	1.77	2.04	2.22	1.98	1.85	1.54	1.64	1.07	0.98	0.92
PAT to CFO Conversion(x)	0.8	0.6	0.8	0.75	1.5	0.17	0.04	0.37	0.91	0.69
Working Capital Days
Receivable Days	25	21	25	47	46	38	56	70	63	53
Inventory Days	4	5	4	5	5	4	14	24	28	32
Payable Days	6,999	6,784	6,332	1,555	1,080	1,967	215	133	115	114

Gujarat Themis Biosyn Ltd Stock News

Gujarat Themis Biosyn Ltd FAQs

What is the share price of Guj. Themis Biosyn?

Company share prices are keep on changing according to the market conditions. The closing price of Guj. Themis Biosyn on 19-Apr-2024 16:01 is ₹379.5.

What is the market cap of Guj. Themis Biosyn?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 19-Apr-2024 16:01 the market cap of Guj. Themis Biosyn stood at ₹2,802.6.

What is the P/E ratio of Guj. Themis Biosyn?

The latest P/E ratio of Guj. Themis Biosyn as of 19-Apr-2024 16:01 is 50.99.

What is the P/B ratio of Guj. Themis Biosyn?

The latest P/B ratio of Guj. Themis Biosyn as of 19-Apr-2024 16:01 is 14.67.

What is the 52-week high and low of Guj. Themis Biosyn?

The 52-week high of Guj. Themis Biosyn is ₹410.0 and the 52-week low is ₹144.5.

What is the TTM revenue of Guj. Themis Biosyn?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Guj. Themis Biosyn is ₹156.3 ( Cr.) .

About Gujarat Themis Biosyn Ltd

Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.

The company has world-wide exports to satisfied customers, having customised facility for all products.

The companyâ€™s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States.

Kopran alongwith Cadila Healthcare Ltd., Lyka Labs Ltd., Themis Chemicals Ltd. and Anant & Co., formed Pharmaceutical Business Group (India) Ltd. in 1990.PBG acquired Gujarat Themis Biosyn Ltd (GTBL) as a sick company from BIFR in collaboration with Yuhan Corporation, South Korea and became Indiaâ€™s first producer of Rifampicin.Yuhan has provided technology for Rifampicin from fermentation and invested in equity also.

Business area of the company